Evidence map›Paper›PMID 41162752›Full record

ArticleThe EMBO journal2025

Structural insights into selective and dual antagonism of EP2 and EP4 prostaglandin receptors.

Yanli Wu, Heng Zhang, Jiuyin Xu, Kai Wu, Wen Hu, Xinheng He, Gaoming Wang, Canrong Wu, H Eric Xu

Abstract read
In one paragraph

Article in The EMBO journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanli Wu *State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China. wuyanli@simm.ac.cn.ORCID http://orcid.org/0009-0005-4562-7397
Heng Zhang *State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.ORCID http://orcid.org/0000-0002-9441-8277
Jiuyin Xu *Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.ORCID http://orcid.org/0009-0001-9411-955X
Kai WuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
Wen HuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
Xinheng HeState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
Gaoming WangDepartment of Biliary-Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Canrong WuResearch Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. wcr13215@rjh.com.cn.ORCID http://orcid.org/0000-0002-2272-3838
H Eric XuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China. eric.xu@simm.ac.cn.ORCID http://orcid.org/0000-0002-6829-8144

Funding

Chinese Academy of Science Strategic Priority Research Program XDB37030103Shanghai Municipal Science and Technology Major Project 2019SHZDZX02Shanghai Post-doctoral Excellence Program 2023707The National Key Research and Development Program of China 2022YFC2703105The National Natural Science Foundation of China 32130022The National Natural Science Foundation of China 32301016The National Natural Science Foundation of China 82121005
6 · The paper itself

Abstract

Prostaglandin E2 (PGE2) signaling through EP2 and EP4 receptors is crucial in regulating inflammation, pain, and cancer progression. While selective and dual antagonists for these receptors hold therapeutic potential, their binding mechanisms and selectivity have remained unclear. In this study, we present cryo-electron microscopy (cryo-EM) structures of human EP2 and EP4 receptors in complex with selective antagonists PF-04418948 and grapiprant, as well as with the dual antagonist TG6-129. These structures reveal distinct binding pockets and interaction networks that dictate antagonist selectivity and efficacy. Notably, TG6-129 displays a novel binding mode, engaging deeply with EP2 while interacting more superficially with EP4 in a two-warhead manner. Furthermore, comparisons of active and inactive receptor structures elucidate the mechanisms underlying EP2 activation and antagonism. Overall, these findings provide a structural framework for understanding prostanoid receptor pharmacology and offer valuable insights for the rational design of improved selective and dual antagonists targeting EP2 and EP4 receptors.

Indexed as

Receptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 SubtypeBinding SitesCryoelectron MicroscopyHumansModels, MolecularProtein BindingPTGER2 protein, humanPTGER4 protein, humanReceptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 SubtypeCryo-EMDual AntagonistEP2EP4Selective Antagonist

Identifiers

PMID41162752
PMCPMC12669672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.